Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 16 |
| Active Pipeline (Recruiting Now) | 4 (2) |
| Completed vs Stopped Early | 7 / 3 (18.8%) |
| Median Closed Actual Enrollment | 105 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| The First Affiliated Hospital of Nanchang University | Nanchang, Jiangxi | 5 |
| The First Affiliated Hospital of Anhui Medical University | Hefei, Anhui | 5 |
| Hubei Cancer Hospital | Wuhan, Hubei | 5 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT07208058 | A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic | Phase III | RECRUITING |
| NCT07453004 | A Study to Evaluate the Efficacy,Safety,Tolerability,Pharmacokinetics,and Immunogenicty of Plonmarlimab in Subjects With Acute Gouty Arthrit | Phase II | RECRUITING |
| NCT06984588 | A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously | Phase II/III | ACTIVE NOT RECRUITING |
| NCT07005336 | A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previ | Phase II | ACTIVE NOT RECRUITING |
| NCT04633057 | A Study to Evaluating the Efficacy and Safety of Recombinant Long-acting Human Growth Hormone (TJ101) in Children With Growth Hormone Defici | Phase III | COMPLETED |
Explore interactive annual charts and M&A subsidiary rollups in the TJ Biopharma Co Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.